Zai Lab Limited American Depositary Shares ZLAB
Analyst Ratings
- Consensus
- Buy — 4 Buy · 0 Hold · 0 Sell (4 analysts)
- Avg. Price Target
- $37.25 (+43.8% upside)
Key Stats
- Today's Range
- $25.33 – $26.26
- 50-Day Range
- $16.26 – $26.66
- 52-Week Range
- $15.96 – $41.20
- Volume
- 1.23 million shs
- Average Volume
- 968K shs
- Market Cap
- $2.86 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 4.71
- Price / Sales
- 6.36
Short Interest
- Short Interest
- 1.02%
- Days to Cover
- 10.16
Financials (TTM)
- Revenue
- $449.61 million
- Net Income
- $-188,213,000
- Net Margin
- -41.86%
- Return on Equity
- -31.01%
- Debt-to-Equity
- —
About Zai Lab Limited American Depositary Shares
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
Related Stocks
Compare head-to-head: ZLAB vs LLY·ZLAB vs JNJ·ZLAB vs ABBV·ZLAB vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.